Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. is enhancing its cancer drug development by expanding strategic collaborations with the University of British Columbia and Pharma Inventor Inc, leveraging the proprietary Deep Docking AI platform to identify promising drug candidates. These alliances are set to rapidly advance selected compounds through in-house validation, aiming to move them towards clinical trials and create shareholder value. The company’s focus on DNA-damage response technologies is poised to generate new cancer treatments.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
